A Phase 2 interventional study of phase 2A Chlorthalidone and phase 2A Spironolactone in Hypertension Treated With Antihypertensive Drugs and Chronic Kidney Disease, 3B and 4, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development — 5 open to participants now, 7 under way, none of them phase 3. Renal Insufficiency, Chronic · VA Office of Research and Development.
Among the 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development, this one is the 7th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, and was the 21st registered.
3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →5 of the 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 55+
VA Office of Research and Development · Sites in United States
Ages 19+
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 100 across the 21 interventional studies, 117 across the 1 observational. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
3 of the studies in Renal Insufficiency, Chronic by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05546099VA Office of Research and DevelopmentPatient-driven Management of BP in CKD | 2026-12-15 |
| NCT04064086VA Office of Research and DevelopmentTrial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans | 2026-12-31 |
| NCT05465044VA Office of Research and DevelopmentIncremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets) | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Renal Insufficiency, Chronic by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD. Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.
Highly prevalent among patients with chronic kidney disease (CKD) , poor blood pressure (BP) control is a modifiable risk factor for both kidney failure progression and cardiovascular (CV) disease. Although the mineralocorticoid receptor antagonist (MRA) spironolactone (SPL) is recommended to treat resistant hypertension in patients with CKD, 34% discontinue SPL within 12 weeks, mostly due to hyperkalemia. The potassium (K) binding agent patiromer reduced the discontinuation rate to 14%, but the added expense and potential drug interactions are of concern. SPL, a steroidal MRA, reduces albuminuria and rates of decline in eGFR. In type 2 diabetes and CKD, the non-steroidal MRA finerenone reduces kidney failure and CV outcomes but is not indicated for the treatment of hypertension. Due to concern of hyperkalemia, SPL is barely prescribed in these patients. In 2021, the investigators reported that chlorthalidone (CTD) in people with advanced CKD was effective in lowering BP and albuminuria by 50%. However, reversible changes in kidney function and hypokalemia were common. The investigators believe that a very low dose combination strategy of CTD + SPL will be effective in lowering BP, maintaining K, and providing target organ protection. However, the optimal dose to maintain K and lower BP remains unclear. To test this hypothesis, the investigators propose a pilot proof-of-concept study (phase 2A) followed by a larger phase 2B study. Proof of Concept, phase 2A: To test the hypothesis that low or very low dose CTD combined with SPL will improve BP, the investigators will perform a pilot, single-center, placebo-controlled, double-blind, randomized trial among patients with CKD and poorly controlled hypertension. After a two-week, patient-blind, placebo run-in, the investigators will randomize 50 hypertensive people to one of 4 groups in equal numbers: placebo; CTD very low dose; SPL very low dose QD; or a combination of CTD very low dose + SPL very low dose for 6 weeks. At 6 weeks, doses will be doubled for a further 6 weeks. The primary endpoint will be assessed by change from baseline to 6 weeks and 12 weeks in systolic AOBP and serum K for the combination group compared to placebo. If CTD + SPL is more effective than placebo, the investigators will perform the phase 2B trial. In this trial, the investigators will test the hypothesis that among patients with moderate to advanced CKD and poorly controlled hypertension, compared to add-on SPL or add-on CTD, treatment over 12 weeks with add-on combination of spironolactone (SPL) and chlorthalidone (CTD) will more effectively lower unattended systolic automated office blood pressure (uAOBP). Furthermore, combination therapy will reduce albuminuria more than either drug alone providing evidence for target organ protection. CTD will produce these effects by further reducing extracellular fluid volume in combination with SPL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hypertension
Treatment with antihypertensive drugs
Exclusion Criteria:
Use of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
phase 2A
Drug: phase 2A Chlorthalidone · Drug: phase 2A Spironolactone · Drug: phase 2A Chlorthalidone + Spironolactone
phase 2A Chlorthalidone(CTD) very low dose (VLD) x 6 weeks
Drug: phase 2A Chlorthalidone
phase 2A Spironolactone(SPL) very low dose (VLD) x 6 weeks
Drug: phase 2A Spironolactone
phase 2A Chlorthalidone(CTD) VLD + Spironolactone(SPL) VLD x 6 weeks
Drug: phase 2A Chlorthalidone + Spironolactone
phase 2B Chlorthalidone(CTD) low dose (LD) x 12 weeks
Drug: phase 2B Chlorthalidone LD + Spironolactone LD
phase 2B Spironolactone(SPL) low dose (LD) x 12 weeks
Drug: phase 2B Chlorthalidone LD + Spironolactone LD
phase 2B Chlorthalidone(CTD) VLD + Spironolactone(SPL) VLD x 12 weeks
Drug: phase 2B Chlorthalidone LD + Spironolactone LD
phase 2B Chlorthalidone(CTD) LD + Spironolactone(SPL) LD x 12 weeks
Drug: phase 2B Chlorthalidone LD + Spironolactone LD
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
compare combination LD with SPL LD at 12 weeks
Unattended systolic automated office blood pressure in phase 2A
phase 2A: the primary endpoint will be assessed by change from baseline to 6 weeks and 12 weeks in systolic AOBP for the combination group compared to placebo.
Time frame: 12 weeks
Serum K phase 2A
phase 2A: the primary endpoint will be assessed by change from baseline to 12 weeks in serum K for the combination group compared to placebo.
Time frame: 12 weeks
Unattended systolic automated office blood pressure in phase 2B
phase 2B: the primary endpoint will be assessed by change from baseline to 12 weeks in systolic AOBP for the combination LD group compared to SPL.
Time frame: 12 weeks
Mediation of BP lowering by volume markers
The investigators will evaluate changes from baseline in the following markers: B-type natriuretic peptide (BNP), seated plasma renin activity and plasma aldosterone, and 24h urinary aldosterone. The investigators will use a mediation model to ascertain the mechanism of BP lowering whether it is via reduction of volume or blockade of the renin-angiotensin system. Each of the 4 mediation variables will be analyzed individually and then in aggregate as prespecified in the statistical analysis plan.
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2032, 65 months later.
Of 58 non-industry phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 62. This study's planned 65 months is above that.
Counting every sponsor, half of 138 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
VA Office of Research and Development →